Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
NCT ID: NCT00863655
Last Updated: 2017-05-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
724 participants
INTERVENTIONAL
2009-06-03
2014-12-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT01674140
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
NCT00107016
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
NCT03176238
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
NCT01743560
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
NCT02291913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Everolimus + Exemestane
Everolimus 10 mg daily in combination with exemestane 25 mg daily
Everolimus
Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Exemestane
Exemestane 25 mg orally daily.
Placebo + Exemestane
Placebo of everolimus in combination with exemestane 25 mg daily
Exemestane
Exemestane 25 mg orally daily.
Everolimus Placebo
Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Everolimus
Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Exemestane
Exemestane 25 mg orally daily.
Everolimus Placebo
Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer
* Postmenopausal women.
* Disease refractory to non steroidal aromatase inhibitors (NSAI),
* Radiological or clinical evidence of recurrence or progression on or after the last systemic therapy prior to randomization.
* Patients must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease as defined above.
Exclusion Criteria
* Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites etc.).
* Patients who received more than one chemotherapy line for Advanced Breast Cancer.
* Previous treatment with exemestane or mTOR inhibitors.
* Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).
* Radiotherapy within four weeks prior to randomization
* Currently receiving hormone replacement therapy,
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ironwood Cancer and Research Centers
Chandler, Arizona, United States
Highlands Oncology Group DeptofHighlandsOncologyGrp(2)
Fayetteville, Arkansas, United States
Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C
Anaheim, California, United States
Comprehensive Blood and Cancer Center Dept. of CBCC (3)
Bakersfield, California, United States
Cancer Care Associates Dept.ofCancerCareAssoc. (2)
Fresno, California, United States
Grass Valley Hematology Oncology Medical Group Dept. of Grass Valley Hem/Onc
Grass Valley, California, United States
Scripps Clinic SC
La Jolla, California, United States
The Angeles Clinic and Research Institute
Los Angeles, California, United States
USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3
Los Angeles, California, United States
Sharp Memorial Hospital SharpClinicalOncologyResearch
San Diego, California, United States
University of California San Francisco UCSF Medical Center
San Francisco, California, United States
Premiere Oncology/Pinnacle Oncology Hematology Dept.ofPremiereOncologyAZ
Santa Monica, California, United States
St Joseph Heritage Healthcare Dept. of RRMG (4)
Santa Rosa, California, United States
Comprehensive Cancer Center - Boca Raton Deerfield Beach
Boca Raton, Florida, United States
Florida Cancer Research Institute
Davie, Florida, United States
Florida Cancer Specialists DeptofFloridaCancerSpecialists
Fort Myers, Florida, United States
Memorial Hospital Memorial Cancer Institute
Hollywood, Florida, United States
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2)
Orlando, Florida, United States
Palm Beach Cancer Institute
West Palm Beach, Florida, United States
Florida Medical Clinic PA Dept.ofFloridaMedicalClinic
Zephyrhills, Florida, United States
Georgia Cancer Specialists. Drug Ship
Decatur, Georgia, United States
Rush University Medical Center Study Coordinator
Chicago, Illinois, United States
Oncology Specialists, SC Dept.of Oncology Specialists
Park Ridge, Illinois, United States
Hematology Oncology of Indiana
Indianapolis, Indiana, United States
Horizon Oncology Center
Lafayette, Indiana, United States
Cancer Center of Kansas Dept.ofCancerCtr.ofKansas
Wichita, Kansas, United States
University of Louisville / James Graham Brown Cancer Center SC
Louisville, Kentucky, United States
Hematology Oncology Clinic Hematology Oncology Clinic (2)
Baton Rouge, Louisiana, United States
Crescent City Research Consortium, LLC Dept of Hem&Onc Specialist - 2
Metairie, Louisiana, United States
Anne Arundel Health System Research Institute Wayson Pavilion
Annapolis, Maryland, United States
Mercy Medical Center Medical Oncology & Hematology
Baltimore, Maryland, United States
Weinberg Cancer Institute at Franklin Square Hospital
Baltimore, Maryland, United States
Maryland Hematology/Oncology Associates, P.A.
Baltimore, Maryland, United States
Frederick Memorial Hospital Dept. of FMH-IRB
Frederick, Maryland, United States
Holy Cross Hospital Holy Cross
Silver Spring, Maryland, United States
Lahey Clinic Dept of Lahey Clinic (2)
Burlington, Massachusetts, United States
Fairview Southdale Medical Oncology Clinic
Edina, Minnesota, United States
St. Louis Cancer & Breast Institute Dept.ofSt.LouisCancer&Breast
St Louis, Missouri, United States
Southeast Nebraska Oncology Cancer Center
Lincoln, Nebraska, United States
Regional Cancer Care Associates Dept. of the CCHD
Cherry Hill, New Jersey, United States
Trinitas Comprehensive Cancer Center Dept. of Trinitas
Elizabeth, New Jersey, United States
University of New Mexico Cancer Research Center Dept of UNM Cancer & Research
Albuquerque, New Mexico, United States
Clinical Research Alliance Dept.ofArenaOncologyAssoc(2)
Lake Success, New York, United States
ProHealth Care
Lake Success, New York, United States
Beth Israel Medical Center Dept.ofBeth Israel Med. Ctr(2)
New York, New York, United States
Weill Cornell Medical College Weill Cornell Med. Ctr.
New York, New York, United States
Hematology Oncology Association of Rockland
Nyack, New York, United States
Marion L. Shepard Cancer Center
Washington, North Carolina, United States
Cancer Centers of Southwest Oklahoma Cancer Research Dept.of Southwest Oklahoma
Lawton, Oklahoma, United States
Cancer Care Associates SC
Tulsa, Oklahoma, United States
Penn State University / Milton S. Hershey Medical Center Division of Oncology (2)
Hershey, Pennsylvania, United States
Medical University of South Carolina -Hollings Cancer Center Dept. MUSC/HollingsCancerCtr
Charleston, South Carolina, United States
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(5)
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center SimmonsComprehensiveCancerCtr.
Dallas, Texas, United States
The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2)
Fort Worth, Texas, United States
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(2)
Houston, Texas, United States
Hope Oncology HOPE Richardson
Richardson, Texas, United States
Northern Utah Cancer Associates SC
Ogden, Utah, United States
Central Utah Clinic CRAD001Y2301
Provo, Utah, United States
Utah Cancer Specialists Dept.of Utah Cancer Spec. (2)
Salt Lake City, Utah, United States
University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(2)
Salt Lake City, Utah, United States
Medical Oncology & Hematology Associates of Northern VA Med. Onc&Hem Assoc. of No.VA
Reston, Virginia, United States
University of Wisconsin Hospital & Clinics UW ComprehensiveCancerCtr(2)
Madison, Wisconsin, United States
Novartis Investigative Site
Nambour, Queensland, Australia
Novartis Investigative Site
Redcliffe, Queensland, Australia
Novartis Investigative Site
Bedford Park, South Australia, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Subiaco, Western Australia, Australia
Novartis Investigative Site
Innsbruck, Austria, Austria
Novartis Investigative Site
Wels, Austria, Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Salzburg, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Leuven, , Belgium
Novartis Investigative Site
Liège, , Belgium
Novartis Investigative Site
Sint-Niklaas, , Belgium
Novartis Investigative Site
Wilrijk, , Belgium
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Uberlândia, Minas Gerais, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Calgary, Alberta, Canada
Novartis Investigative Site
Moncton, New Brunswick, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Cambridge, Ontario, Canada
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Newmarket, Ontario, Canada
Novartis Investigative Site
St. Catharines, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Weston, Ontario, Canada
Novartis Investigative Site
Greenfield Park, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Novartis Investigative Site
Brno, Czech Republic, Czechia
Novartis Investigative Site
Prague, Czech Republic, Czechia
Novartis Investigative Site
Olomouc, CZE, Czechia
Novartis Investigative Site
Menoufiya, Egypt, Egypt
Novartis Investigative Site
Alexandria, , Egypt
Novartis Investigative Site
Cairo, , Egypt
Novartis Investigative Site
La Roche-sur-Yon, , France
Novartis Investigative Site
Le Mans, , France
Novartis Investigative Site
Lyon, , France
Novartis Investigative Site
Marseille, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Rouen, , France
Novartis Investigative Site
Rouen, , France
Novartis Investigative Site
Saint-Herblain Cédex, , France
Novartis Investigative Site
Saint-Nazaire, , France
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Düsseldorf, , Germany
Novartis Investigative Site
Frankfurt, , Germany
Novartis Investigative Site
Mannheim, , Germany
Novartis Investigative Site
München, , Germany
Novartis Investigative Site
München, , Germany
Novartis Investigative Site
Münster, , Germany
Novartis Investigative Site
Trier, , Germany
Novartis Investigative Site
Hong Kong SAR, , Hong Kong
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Szeged, , Hungary
Novartis Investigative Site
Szolnok, , Hungary
Novartis Investigative Site
Brindisi, BR, Italy
Novartis Investigative Site
Catania, CT, Italy
Novartis Investigative Site
Antella - Bagno A Ripoli, FI, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Macerata, MC, Italy
Novartis Investigative Site
Perugia, PG, Italy
Novartis Investigative Site
Torino, TO, Italy
Novartis Investigative Site
Terni, TR, Italy
Novartis Investigative Site
Saronno, Va, Italy
Novartis Investigative Site
Varese, VA, Italy
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Kashiwa, Chiba, Japan
Novartis Investigative Site
Matsuyama, Ehime, Japan
Novartis Investigative Site
Fukuoka, Fukuoka, Japan
Novartis Investigative Site
Kitakyushu, Fukuoka, Japan
Novartis Investigative Site
Maebashi, Gunma, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Kagoshima, Kagoshima-ken, Japan
Novartis Investigative Site
Isehara, Kanagawa, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, Japan
Novartis Investigative Site
Kyoto, Kyoto, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Suita, Osaka, Japan
Novartis Investigative Site
Hidaka, Saitama, Japan
Novartis Investigative Site
Kitaadachi-gun, Saitama, Japan
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan
Novartis Investigative Site
Chuo-ku, Tokyo, Japan
Novartis Investigative Site
Chuo-ku, Tokyo, Japan
Novartis Investigative Site
Koto, Tokyo, Japan
Novartis Investigative Site
Eindhoven, Netherlands, Netherlands
Novartis Investigative Site
Alkmaar, , Netherlands
Novartis Investigative Site
Amsterdam, , Netherlands
Novartis Investigative Site
Dordrecht, , Netherlands
Novartis Investigative Site
Sittard-Geleen, , Netherlands
Novartis Investigative Site
The Hague, , Netherlands
Novartis Investigative Site
Christchurch, Christchurch, New Zealand
Novartis Investigative Site
Lørenskog, , Norway
Novartis Investigative Site
Krakow, , Poland
Novartis Investigative Site
Rzeszów, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Hwasun-gun, Jeollanam-do, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Málaga, Andalusia, Spain
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
Mallorca, Balearic Islands, Spain
Novartis Investigative Site
Palma de Mallorca, Balearic Islands, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Lleida, Catalonia, Spain
Novartis Investigative Site
Terrassa, Catalonia, Spain
Novartis Investigative Site
A Coruña, Galicia, Spain
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain
Novartis Investigative Site
Madrid, Madrid, Spain
Novartis Investigative Site
Madrid, Madrid, Spain
Novartis Investigative Site
Madrid, Madrid, Spain
Novartis Investigative Site
Stockholm, , Sweden
Novartis Investigative Site
Stockholm, , Sweden
Novartis Investigative Site
Uppsala, , Sweden
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Chiang Mai, , Thailand
Novartis Investigative Site
Songkhla, , Thailand
Novartis Investigative Site
Izmir, Turkey, Turkey (Türkiye)
Novartis Investigative Site
Altunizade, , Turkey (Türkiye)
Novartis Investigative Site
Ankara, , Turkey (Türkiye)
Novartis Investigative Site
Broomfield, Chelmsford, United Kingdom
Novartis Investigative Site
Truro, Cornwall, United Kingdom
Novartis Investigative Site
Cardiff, , United Kingdom
Novartis Investigative Site
Nottingham, , United Kingdom
Novartis Investigative Site
Sheffield, , United Kingdom
Novartis Investigative Site
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9.
Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2016 Oct 1;2(10):1310-1315. doi: 10.1001/jamaoncol.2016.1279.
Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol. 2016 Feb 10;34(5):419-26. doi: 10.1200/JCO.2014.60.1971. Epub 2015 Oct 26.
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Ann Oncol. 2014 Dec;25(12):2357-2362. doi: 10.1093/annonc/mdu456. Epub 2014 Sep 17.
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA 3rd. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol. 2014 Apr;25(4):808-815. doi: 10.1093/annonc/mdu009. Epub 2014 Mar 10.
Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Epub 2013 Oct 25.
Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA 3rd. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin. 2013 Nov;29(11):1463-73. doi: 10.1185/03007995.2013.836078. Epub 2013 Sep 4.
Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer. 2014 Nov;21(6):703-14. doi: 10.1007/s12282-013-0444-8. Epub 2013 Feb 13.
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-008698-69
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CRAD001Y2301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.